This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Cohen, S. M. Articles by Smith, R. A. Search for Related Content PubMed PubMed Citation Articles by Cohen, S. M. Articles by Smith, R. A.

Acrolein Initiates Rat Urinary Bladder Carcinogenesis¹

Department of Pathology and Microbiology and Eppley Institute, University of Nebraska Medical Center, Omaha, Nebraska 68198-3135

Acrolein, a reactive, ,ß-unsaturated aldehyde which is ubiquitous in the environment, forms DNA adducts, is mutagenic, and is teratogenic. However, studies have not indicated a carcinogenic effect in rodent bioassays. Since it is present in cigarette smoke and is the toxic metabolite of cyclophosphamide with respect to the urinary tract, we investigated the possibility that acrolein might have carcinogenic activity toward the rat urinary bladder. We also evaluated whether it possessed initiating and/or promoting activity.

To evaluate initiating activity, acrolein was administered at a dose of 2 mg/kg i.p. twice a week for 6 weeks followed by uracil as 3% of the diet for 20 weeks and then control diet for 6 weeks. N-[4-(5-Nitro-2-furyl)-2-thiazolyl]formamide (FANFT) as 0.2% of the diet followed by uracil was used as a positive control, and a negative control group was administered solvent control (water) i.p. during the 6-week initiation period followed by uracil. Acrolein followed by uracil produced an incidence of 18 of 30 rats (60%) with papilloma compared to 8 of 30 rats (27%) treated with solvent control followed by uracil. FANFT followed by uracil produced an incidence of 70% carcinomas and 30% papillomas, clearly indicating that it is a much more potent initiating agent than acrolein. Acrolein for 6 weeks followed by control diet produced no tumors.

To evaluate promoting activity, groups of rats were fed FANFT for 6 weeks followed by acrolein. Acrolein administered during the initial 6 weeks and continued for the second phase of the experiment (to evaluate complete carcinogenic activity) resulted in severe toxicity. Administration of acrolein had to be terminated after 21 weeks of the experiment. The animals were maintained for 53 weeks of the experiment without further chemical treatment, and there was no evidence of papilloma or carcinoma development.

This study clearly indicates that acrolein has initiating activity for the urinary bladder when administered by i.p. injection to the male F344 rat, but toxicity precluded evaluation of its promoting or complete carcinogenic activity.

¹ This research was supported in part by USPHS Grants CA44886 and CA36727 from the National Cancer Institute.

² To whom requests for reprints should be addressed, at the Department of Pathology and Microbiology, University of Nebraska Medical Center, 600 South 42nd Street, Omaha, NE 68198-3135.

³ Present address: Department of Urology, Nagoya City University Medical School, Nagoya, Japan.

Received 12/30/91. Accepted 4/22/92.

This article has been cited by other articles:

				M. D. Stout, E. Bodes, R. Schoonhoven, P. B. Upton, G. S. Travlos, and J. A. Swenberg Toxicity, DNA Binding, and Cell Proliferation in Male F344 Rats following Short-term Gavage Exposures to Trans-2-Hexenal Toxicol Pathol, February 1, 2008; 36(2): 232 - 246. [Abstract] [Full Text] [PDF]

				S.-i. Kim, G. P. Pfeifer, and A. Besaratinia Lack of Mutagenicity of Acrolein-Induced DNA Adducts in Mouse and Human Cells Cancer Res., December 15, 2007; 67(24): 11640 - 11647. [Abstract] [Full Text] [PDF]

				S. S. Hecht Smoking and lung cancer--a new role for an old toxicant? PNAS, October 24, 2006; 103(43): 15725 - 15726. [Full Text] [PDF]

				Z. Feng, W. Hu, Y. Hu, and M.-s. Tang From the Cover: Acrolein is a major cigarette-related lung cancer agent: Preferential binding at p53 mutational hotspots and inhibition of DNA repair PNAS, October 17, 2006; 103(42): 15404 - 15409. [Abstract] [Full Text] [PDF]

				Y. Kawai, A. Furuhata, S. Toyokuni, Y. Aratani, and K. Uchida Formation of Acrolein-derived 2'-Deoxyadenosine Adduct in an Iron-induced Carcinogenesis Model J. Biol. Chem., December 12, 2003; 278(50): 50346 - 50354. [Abstract] [Full Text] [PDF]

				A. Furuhata, T. Ishii, S. Kumazawa, T. Yamada, T. Nakayama, and K. Uchida N{epsilon}-(3-Methylpyridinium)lysine, a Major Antigenic Adduct Generated in Acrolein-modified Protein J. Biol. Chem., December 5, 2003; 278(49): 48658 - 48665. [Abstract] [Full Text] [PDF]

				S. Biswal, T. Maxwell, T. Rangasamy, and J. P. Kehrer Modulation of benzo[a]pyrene-induced p53 DNA activity by acrolein Carcinogenesis, August 1, 2003; 24(8): 1401 - 1406. [Abstract] [Full Text] [PDF]

				I.-Y. Yang, H. Miller, Z. Wang, E. G. Frank, H. Ohmori, F. Hanaoka, and M. Moriya Mammalian Translesion DNA Synthesis across an Acrolein-derived Deoxyguanosine Adduct. PARTICIPATION OF DNA POLYMERASE eta IN ERROR-PRONE SYNTHESIS IN HUMAN CELLS J. Biol. Chem., April 11, 2003; 278(16): 13989 - 13994. [Abstract] [Full Text] [PDF]

				I. G. Minko, M. T. Washington, M. Kanuri, L. Prakash, S. Prakash, and R. S. Lloyd Translesion Synthesis past Acrolein-derived DNA Adduct, gamma -Hydroxypropanodeoxyguanosine, by Yeast and Human DNA Polymerase eta J. Biol. Chem., January 3, 2003; 278(2): 784 - 790. [Abstract] [Full Text] [PDF]

				A. Furuhata, M. Nakamura, T. Osawa, and K. Uchida Thiolation of Protein-bound Carcinogenic Aldehyde. AN ELECTROPHILIC ACROLEIN-LYSINE ADDUCT THAT COVALENTLY BINDS TO THIOLS J. Biol. Chem., July 26, 2002; 277(31): 27919 - 27926. [Abstract] [Full Text] [PDF]

				M. Kanuri, I. G. Minko, L. V. Nechev, T. M. Harris, C. M. Harris, and R. S. Lloyd Error Prone Translesion Synthesis Past gamma -Hydroxypropano Deoxyguanosine, the Primary Acrolein-derived Adduct in Mammalian Cells J. Biol. Chem., May 17, 2002; 277(21): 18257 - 18265. [Abstract] [Full Text] [PDF]

				H M Coutinho, J W Groothoff, M Offringa, M P Gruppen, and H S A Heymans De novo malignancy after paediatric renal replacement therapy Arch. Dis. Child., December 1, 2001; 85(6): 478 - 483. [Abstract] [Full Text] [PDF]

				W. Takabe, E. Niki, K. Uchida, S. Yamada, K. Satoh, and N. Noguchi Oxidative stress promotes the development of transformation: involvement of a potent mutagenic lipid peroxidation product, acrolein Carcinogenesis, June 1, 2001; 22(6): 935 - 941. [Abstract] [Full Text] [PDF]

				D. Schuler and E. Eder Detection of 1,N2-propanodeoxyguanosine adducts of 2-hexenal in organs of Fischer 344 rats by a 32P-post-labeling technique Carcinogenesis, July 1, 1999; 20(7): 1345 - 1350. [Abstract] [Full Text] [PDF]

				Y. Cai, M. H. Wu, S. M. Ludeman, D. J. Grdina, and M. E. Dolan Role of O6-Alkylguanine-DNA Alkyltransferase in Protecting against Cyclophosphamide-induced Toxicity and Mutagenicity Cancer Res., July 1, 1999; 59(13): 3059 - 3063. [Abstract] [Full Text] [PDF]

				L. A. VanderVeen, M. F. Hashim, L. V. Nechev, T. M. Harris, C. M. Harris, and L. J. Marnett Evaluation of the Mutagenic Potential of the Principal DNA Adduct of Acrolein J. Biol. Chem., March 16, 2001; 276(12): 9066 - 9070. [Abstract] [Full Text] [PDF]

				I.-Y. Yang, M. Hossain, H. Miller, S. Khullar, F. Johnson, A. Grollman, and M. Moriya Responses to the Major Acrolein-derived Deoxyguanosine Adduct in Escherichia coli J. Biol. Chem., March 16, 2001; 276(12): 9071 - 9076. [Abstract] [Full Text] [PDF]